GlassScriptPhysician profile
Michael C Angelillo
NPI 1386153807
$904.30
in general payments reported to CMS, 2019-2025
15 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2021: $16.93 · 2022: $120 · 2023: $79.65 · 2024: $148 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $587.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $135.03 | 2019-2022 | |
| Pfizer INC. | $124.67 | 2021-2025 | |
| Abbvie INC. | $106.08 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $105.24 | 2022-2025 | |
| Glaxosmithkline, LLC. | $102.06 | 2022-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $92.69 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $50.49 | 2024-2025 | Veozah |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $41.18 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.29 | 2022-2025 | Xifaxan |
| Horizon Therapeutics Plc | $26.28 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $18.77 | 2024 | |
| Esperion Therapeutics, INC. | $18.04 | 2024 | Nexletol |
| Amgen INC. | $16.86 | 2025 | Repatha, Otezla |
| Kowa Pharmaceuticals America, INC. | $16.60 | 2019 | |
| Edwards Lifesciences Corporation | $16.02 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Angelillo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.